{
  "docId": "019de074-559c-76fa-9457-a7d91e9a06c5",
  "docSlug": "15199f0b497c4ef204a0760da27401b3",
  "documentTitle": "Dare Bioscience | Investor Presentation Deck | 54 slides",
  "authorId": "dare-bioscience",
  "authorName": "Daré Bioscience",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-02-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.2938006,
  "pageNumber": 19,
  "pageCount": 54,
  "prevPage": 18,
  "nextPage": 20,
  "slideType": "traction",
  "function": "show_traction",
  "density": "dense",
  "nDataPoints": 2,
  "notes": "The slide highlights a key partnership milestone and the associated financial structure (upfront payment and potential milestones).",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-559c-76fa-9457-a7d91e9a06c5/19",
  "deckHref": "/decks/019de074-559c-76fa-9457-a7d91e9a06c5",
  "deckJsonHref": "/decks/019de074-559c-76fa-9457-a7d91e9a06c5.json",
  "deckAnchorHref": "/decks/019de074-559c-76fa-9457-a7d91e9a06c5#slide-19",
  "components": [
    {
      "bbox": {
        "h": 0.291,
        "w": 0.478,
        "x": 0.425,
        "y": 0.287
      },
      "kind": "callout",
      "text": "• The license became effective June 2022.\n• Daré received a $10 million upfront payment from Organon in 3Q 2022.\n• Daré is eligible to receive potential milestone payments of up to $182.5 million and tiered double-digit royalties based on net sales.",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4b84099d-d153-44e3-925e-37cecbcf5260",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.076,
        "w": 0.806,
        "x": 0.097,
        "y": 0.685
      },
      "kind": "paragraph",
      "text": "We believe Organon shares our commitment to advance critically needed innovations in women’s health. We are excited to be collaborating with one of the premier companies in women’s health as we believe that Organon’s commercial capabilities will ensure that XACIATO reaches the women most impacted by bacterial vaginosis.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8b6f9773-2c7c-4521-955c-491024e87288",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.265,
        "w": 0.396,
        "x": 0.097,
        "y": 0.275
      },
      "kind": "paragraph",
      "text": "March 2022 – Organon and Daré announced they entered into an agreement whereby Organon will license global rights to XACIATO. The license became effective June 2022.\n\nOrganon is a global healthcare company formed through a spin-off from Merck & Co., Inc., Rahway, NJ, USA, (NYSE: MRK) known as MSD outside of the United States and Canada, to focus on improving the health of women throughout their lives.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e4d83eea-7cb6-4aca-8cf8-74aa5dfda95a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.018,
        "w": 0.548,
        "x": 0.031,
        "y": 0.813
      },
      "kind": "source-note",
      "text": "1. https://ir.darebioscience.com/news-releases/news-release-details/organon-enters-global-license-agreement-commercialize-dare",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8c17b4e4-4db7-4365-97fa-fb430f26b057",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.035,
        "w": 0.684,
        "x": 0.158,
        "y": 0.158
      },
      "kind": "title",
      "text": "XACIATO - Commercial License Agreement with Organon",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "02ac72af-860b-4710-8b08-c579783f8b69",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 54,
      "from": 17,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "2cf418f8-2568-4e9a-bf9d-f55bdd0bfb9e",
      "evidence": "The deck implies that inaction in women's health has significant consequences",
      "position": 0,
      "objective": "What is the cost of inaction in women's health?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}